Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a development and manufacturing agreement with ZZ Biotech, LLC. According to the agreement, Laureate will produce Activated Protein C variant under cGMP conditions. Terms of the manufacturing agreement were not disclosed.
"We are pleased that ZZ Biotech has chosen Laureate as their manufacturing partner," said Robert J. Broeze, Ph. D., President & CEO of Laureate. "We will work closely with the ZZ Biotech team and help them drive their product from development into the clinic."
"Laureate Pharma has a proven track record in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-scale grade materials," said Berislav V. Zlokovic, M.D., Ph.D. Founder and Chief Scientific Officer of ZZ Biotech, Dean's Professor and Director Center for Neurodegenerative and Vascular Brain Disorders at the University of Rochester, NY. "This agreement enables us to operationally leverage Laureate's expertise and infrastructure while we seek to establish new treatment for stroke and neurodegenerative disorders."